Stand aside — setup invalidated
Setup score 72, but distribution days reach 5 or more — stand aside until the condition resets.
Simple research view
BMY · Bristol-Myers Squibb Company
$63.75 -1.02% Sep 10 close
Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.
$BMY
Bristol-Myers Squibb CompanyBristol-Myers Squibb Company is a large-cap Pharmaceuticals: Major company in the Health Technology sector with a market cap of $130B.
Verdict · setup score 72/100 · data Sep 10 close · 1 session old
Stand aside — setup invalidated
Setup score 72, but distribution days reach 5 or more — stand aside until the condition resets.
Earnings
Normal technical setup
No sourced report date
Event risk is not modelled for this symbol
Deterministic evidence
BMY-1.02%
Sector proxy · XLV-0.55%
Broad market · SPY-0.60%
Session internals Weak
Rule: closed flat-to-down and in the bottom third of the range. Judged on internals, not on the size of the move.
Vs prior close-1.02%
From the open-1.80%
Range position2%
GapNo gap
QQQ confirmationConfirming (-1.06%)
SMH confirmationConfirming (-2.44%)
Ask a Legend to interpret this evidence → Commentary only — never scanner evidence or a sizing recommendation.
More stats
52W Low
$42.52
Tight Wks
0
Base
B2
SMA 200
$58.41
RS Line vs High
-11.0%
RS Line Slope
+1.2% ▲
Group Rank
#27/58
ADR%
2.0%
ATR(14)
$1.36 (2.1%)
Vol Pace (live)
N/A
U/D Vol
1.23
A/D Days
19A / 10D
A/D Rating
A+
VDU Bars
0/10 d
BMY Chart
Interactive price, volume, RS, RSI, and MACD charts are available after sign in.
Technical Analysis Report Card
$BMY · $63.75 · as of 2026-09-10 · multi-factor read
50
/ 100
Reference read from price & volume only — the verdict at the top of the page decides the action.
Trend · Daily / Weekly / Monthly
Daily
▬ Sideways / consolidating
Weekly
▬ Sideways / consolidating
Monthly
▬ Sideways / consolidating
Moving Averages
50-day$63.28 ↑
100-day$60.16 ↑
200-day$58.41 ↑
Bullish (50 > 200)
RSI (14)
Reading42.8 · Bearish
Bearish momentum — sellers in control.
MACD (12/26/9)
StateWeakening
Histogram-0.573
Weakening — MACD slipped below its signal line. Histogram contracting.
Bollinger Bands (20,2)
%B / Width7% · 8.6%
Near the lower band — under pressure or oversold.
Volume · Buyer vs Seller
Up/Down vol1.23 · Neutral
Rel volume0.63×
Balanced — up/down volume is roughly even; no clear hand. Recent volume is easing versus its baseline.
Support & Resistance
R · $68.3752-week high
Price · $63.75now
S · $63.00swing level
S · $59.23swing level
S · $56.92swing level
Fibonacci · Uptrend swing
23.6%$65.05
38.2% ◄ price here$62.83
50.0%$61.04
61.8%$59.25
78.6%$56.69
Retracement support zones measured from the recent swing low up to the high.
The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for BMY — plus the full 500+ symbol scanner and Ask-the-Legends chat.
Start your 7-day free trial →
Above 200-day MA50/200 bullish
Want this read in a legend's voice?
Ask a Legend about BMY
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts
6 methodology checks
Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.
Council consensus:
5 of 6 legends are Watching — building, not yet a confirmed buy.
Watch
Minervini B
Trend-template read: 8/10 pass; wait for the soft misses to improve.
Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $63.75, MA150 $60.06, MA200 $58.41
1.2 150-day MA > 200-day MAMA150 $60.06 vs MA200 $58.41
Failing evidence
1.8 RS rank ≥ 70 (prefer ≥ 85)RS rank 51
2. Revenue growth ≥ 20% YoY-0.2% YoY
Avoid
O'Neil D
CANSLIM read: fails L: RS rank ≥ 80 (IBD leadership).
Passing evidence
C: Quarterly EPS acceleration ≥ 25%+29.1% QoQ
A: Annual earnings & revenue qualityRev -0.2% | ROE 46.8%
Failing evidence
L: RS rank ≥ 80 (IBD leadership)RS rank 51
S: Volume ≥ 40% above average on breakoutVolume ratio 0.63x
Watch
Weinstein C
Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.
Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $63.75 vs MA200 $58.41
Failing evidence
Volume expansion above averageVolume ratio 0.63x
Relative strength ≥ 60RS 51
Watch
Livermore B
Pivotal-point read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$63.75
Distance from 52-week high7.1% below high
Failing evidence
Relative strengthRS 51
Volume vs average0.63x
Watch
Darvas B
Box-theory read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$63.75
Distance from 52-week high7.1% below high
Failing evidence
Relative strengthRS 51
Volume vs average0.63x
Watch
Wyckoff B
Supply-and-demand read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$63.75
Distance from 52-week high7.1% below high
Failing evidence
Relative strengthRS 51
Volume vs average0.63x
Base & Breakout
Breakout follow-through
No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?
RS Line vs SPY
52-week relative strength · blue = RS line · dashed = MA50 · dot = NH
▲ Rising
Accumulation / Distribution
last 65 sessions · green = acc on high vol · red = dist on high vol
Net +9
Fundamentals & leadership quality — Minervini’s published criteria · 5/7 met
B
5/7 criteria
Separate score from the Minervini Trend Template (7/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
EPS acceleration ≥25% QoQ
+29%
Revenue growth ≥20% YoY
-0%
Gross margin ≥30%
72%
ROE ≥17%
47%
RS rating ≥80 (leadership)
51
Stage 2 uptrend (Weinstein)
Stage 2
Within 25% of 52W high
-7.1%
Method Playbook
Trade it like Livermore
EXACT LEVELS · PRO
Livermore B · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.
Pivot
Pro levelPublished-method rule: Treat the resistance break as a pivotal point only while the primary trend and relative strength remain aligned.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro levelPublished-method rule: Wait for price and volume to confirm the pivotal-point break; anticipation below the line is not confirmation.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro levelPublished-method rule: Place the initial stop below the pivotal line or the reaction low that would prove the breakout false.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-basedPublished-method rule: Raise protection beneath successive higher reaction lows as the trend advances; never move a protective line farther away.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro levelPublished-method rule: Exit when price fails the pivotal line, breaks the latest meaningful reaction low, or shows abnormal reversal action.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →
Pattern Analysis
72
setup score
RS Score
51
Trend template
7/8
Why This Setup?
Trend Only · schematic
Gatekeeper 7/8 | Strong trend (7/8) | Stage 2
The Universal Edge Check · context only
What the setup still has going for it, recorded for later. The verdict above stands — these principles do not overrule it.
1/7
universals met
- A relative-strength leader — not met RS rank 42 — laggard
- Risk is defined — not met No stop — undefined risk
- Asymmetric reward — partly met No target set
- Clear of earnings — partly met Report date unknown
- Not chasing (in range) — partly met Pivot distance unknown
- Volume confirms — partly met 0.6× average — light
- In a confirmed uptrend — met Stage 2 · Trend template 7/8
Minervini Trend Template
7/8Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.
Price above SMA 150 & 200
$63.75 vs SMA150 $60.06 / SMA200 $58.41
SMA 150 above SMA 200
SMA150 $60.06 vs SMA200 $58.41
SMA 200 trending up
Slope +2.02 over 20 days
SMA 50 above SMA 150 & 200
SMA50 $63.28
Price above SMA 50
$63.75 vs SMA50 $63.28
30%+ above 52-week low
+49.9% from $42.52
Within 25% of 52-week high
-7.1% from $68.64
RS score above 70
RS 51
Fundamentals
52W Range
81%
Mkt Cap SEC
130.2B
EPS QoQ
+29%
Rev YoY
-0%
ROE
47%
Gross Margin
72%
D/E
2.44
EPS TTM
$3.46
P/E TTM
18.4x
Float
2.0B
Company
Company profile
Bristol-Myers Squibb Company
Weekly Context
Multi-timeframe signals from weekly barsW. Trend
8/8
W. RS
80
W. Support
$53.44
W. Resist
$68.64
Weekly Structure
Trend
Neutral
Tight Weeks
0
Confirmation
Neutral
Scan History
Sep 11
Trend Only
✓ Gate
72
Sep 11
Trend Only
✓ Gate
71
Sep 11
Trend Only
✓ Gate
68
Sep 10
Trend Only
✓ Gate
72
0.0%
Sep 09
Trend Only
✓ Gate
73
-1.0%
Sep 09
Trend Only
✓ Gate
72
-1.0%
Get the full picture on BMY
Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 500+ symbols daily.
Start 7-Day Free Trial